Physician profile
David Bortz
NPI 1336291665
$1,733.37
in general payments reported to CMS, 2019-2025
14 companies · $28.29 in 2025
The $28.29 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $324 · 2021: $444 · 2022: $249 · 2023: $142 · 2024: $213 · 2025: $28.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $384.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $377.49 | 2019-2025 | Mounjaro |
| Abbvie INC. | $336.00 | 2020-2021 | |
| Novo Nordisk INC | $275.35 | 2022-2024 | Wegovy, Saxenda |
| Allergan, INC. | $178.66 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $137.91 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.68 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $117.57 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $96.57 | 2021 | |
| Amgen INC. | $31.63 | 2019-2020 | |
| Astellas Pharma US INC | $21.25 | 2019 | |
| Intercept Pharmaceuticals, INC. | $13.88 | 2020 | |
| Eisai INC. | $13.66 | 2020 | |
| Pfizer INC. | $12.72 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bortz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.